No intervention
OtherNo intervention.
NCT Number: NCT06917430
Background and aim:
Neuromuscular diseases encompass a range of conditions affecting muscle cells, nerves, or the interaction between the two. A common pathological feature of these conditions is the pro-gressive replacement of muscle tissue with fat, which can be visualised using magnetic reso-nance imaging (MRI). MRI-based fat quantification serves as a key biomarker for disease characterisation, progression tracking, and treatment assessment. Currently, manual segmenta-tion of MRI scans for fat quantification is very time-consuming, requiring individual muscle delineation. Therefore, an artificial intelligence (AI) model is being developed to automate the segmentation. The aim of this study is to validate this AI model and assess its possibilities and limitations.
Method:
The study is ongoing. Retrospective MRI scans of patients with four different muscle diseases (anoctaminopathy, Becker muscular dystrophy, facioscapulohumeral muscular dystrophy, and hypokalemic periodic paralysis) are collected and manual delineation used for training the AI-model is being performed. The intramuscular fat fraction of individual muscles of the pelvis, thigh, and calf will be analysed using the AI model. The performance of the AI model will be compared to manual segmentation. The AI will be evaluated on metrics such as segmentation accuracy and time efficiency.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
No intervention.
Time frame: Analysis of the muscle fat fraction takes 1 hour per patient.
The mean difference in MRI assessed intramuscular fat fraction in the lower back, thigh, and calf muscles between manual outlining and the outlining by the AI model.
Time frame: The analysis of the MRI takes around an hour
Investigate if the difference between manual outlining and AI outlining increases the more advanced stage the disease is. A correlation analysis will be made between manual/AI differences and fat fraction in lower back, thigh, and calf.
Contact information is provided by the study sponsor or research team.
Bjørk Teitsdóttir, Medical student
CONTACT
John Vissing, Professor
CONTACT
Rigshospitalet, Denmark
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05019625
Becker Muscular Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Boston, Massachusetts, United States
View Trial DetailsNCT00104078
Becker Muscular Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07402122
Becker Muscular Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Essen, Germany
View Trial DetailsNCT06540365
Becker Muscular Dystrophy, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
View Trial Details